论文部分内容阅读
克冠(艹卓)(dilazep)为一新合成的冠状动脉扩张剂,应用于冠心病的治疗。已知克冠(艹卓)抑制体内某些组织对腺苷的摄取,提高血中的腺苷浓度,从而扩张冠状动脉。本文研究了克冠(艹卓)体外和体内给药对家兔血小板聚集的影响。在4.8～10×10~(-4)M浓度范围内,克冠(艹卓)体外给药能显著地抑制ADP(终浓度1.2×10~(-5)M)诱导的兔血小板聚集(P<0.05)。4.8×10~(-4)M的克冠(艹卓)抑制率为26%,10~(-3)M的克冠(艹卓)抑制率为90.6%,抑制率与药物浓度呈正相关。体内给药实验中,家兔腹腔注射3mg/kg克冠(艹卓)后30分钟,ADP诱导的血小板聚集受到抑制,抑制率6%(P>0.05);给药后60分钟,抑制作用达到高峰,抑制率18.8%(P<0.01);以后,抑制作用缓慢下降,120分钟时抑制
Dilazep (dilazep) is a newly synthesized coronary dilating agent used in the treatment of coronary heart disease. It is known that Gram-Crest inhibits the uptake of adenosine by certain tissues in the body and increases the concentration of adenosine in the blood, thereby expanding the coronary artery. In this paper, we investigated the effect of g Coronetine on platelet aggregation in rabbits in vitro and in vivo. In the concentration range of 4.8 ~ 10 × 10 ~ (-4) M, K + administration significantly inhibited platelet aggregation induced by ADP (final concentration 1.2 × 10 -5 M) (P <0.05). The inhibition rate of Keguan with 4.8 × 10 ~ (-4) M was 26%, and that of 10 ~ (-3) M was 90.6%. The inhibition rate was positively correlated with the drug concentration. In vivo, 30 min after intraperitoneal injection of 3 mg / kg gavage, ADP-induced platelet aggregation was inhibited with a 6% inhibition rate (P> 0.05); at 60 min after administration, the inhibitory effect was achieved Peak, the inhibition rate was 18.8% (P <0.01); later, the inhibition slow down, inhibition at 120 minutes